Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) reported that the Phase 3 CheckMate-651 trial comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) against the EXTREME regimen for squamous cell carcinoma of the head and neck did not meet its primary endpoints. Although a trend favoring overall survival was noted in patients with tumors expressing PD-L1 (CPS ≥ 20), results lacked statistical significance. Safety profiles were consistent with prior studies. The company remains committed to ongoing research and trials for this challenging cancer type.
Bristol Myers Squibb (NYSE: BMY) has received approval from the European Commission for Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of dMMR or MSI-H metastatic colorectal cancer after prior chemotherapy. This marks the first dual immunotherapy for GI tumors in the EU, based on the CheckMate -142 trial which demonstrated a 64.7% objective response rate. The combination has also been FDA-approved since July 2018 and received prior approval in Japan. With this, patients in the EU gain a significant new treatment option.
Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo for adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer post-neoadjuvant chemoradiotherapy. This positive opinion follows Phase 3 CheckMate -577 trial results, which showed that Opdivo improved disease-free survival compared to placebo. The European Commission will now review the recommendation.
Bristol Myers Squibb (NYSE: BMY) announced that the CHMP has recommended Conditional Marketing Authorization for Abecma (idecabtagene vicleucel), a CAR T cell therapy for relapsed and refractory multiple myeloma. This recommendation follows positive outcomes from the Phase 2 KarMMa study involving 128 patients. The European Commission will review this recommendation, with a decision expected within 67 days. Abecma targets patients with limited options, marking a potential advancement in their treatment. The therapy has previously been granted access to the EMA's PRIME scheme.
Bristol Myers Squibb (NYSE: BMY) received full Marketing Authorization from the European Commission for Onureg (azacitidine tablets) as a maintenance therapy for adults with acute myeloid leukemia (AML) in complete remission. Onureg becomes the first once-daily oral maintenance therapy to showcase significant survival benefits across various AML subtypes. The approval follows the QUAZAR AML-001 Phase 3 clinical trial, which reported a median overall survival of 24.7 months for patients on Onureg compared to 14.8 months on placebo. The treatment aims to address the unmet needs for AML patients not eligible for stem cell transplantation.
Bristol-Myers Squibb (NYSE: BMY) and Eisai Co., Ltd. have announced a collaboration for the co-development and commercialization of MORAb-202, an antibody drug conjugate targeting advanced solid tumors. Eisai will conduct studies in Japan and the U.S., moving toward registrational stages next year. Bristol-Myers Squibb will invest $650 million, including $200 million for R&D, and up to $2.45 billion in potential milestones. Both companies will share profits and costs in specified territories, with Bristol-Myers Squibb handling regions outside these areas.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.49 per share on its common stock, payable on August 2, 2021, with a record date of July 2, 2021. Additionally, a $0.50 dividend on its convertible preferred stock will be paid on September 1, 2021, to stockholders on record by August 10, 2021. The company continues its commitment to returning value to its shareholders.
Bristol Myers Squibb (BMY) and Acceleron Pharma (XLRN) presented promising results from the Phase 2 BEYOND study on Reblozyl® (luspatercept-aamt) for adult patients with non-transfusion dependent beta thalassemia at the EHA 2021 Virtual Congress. 77.7% of patients treated with Reblozyl showed a hemoglobin increase of ≥1.0 g/dL, compared to 0% in the placebo group. The study highlights Reblozyl's potential in improving the quality of life for patients, addressing a significant unmet medical need. The study involved 145 patients over a 48-week treatment period, showing higher efficacy than placebo.
Bristol Myers Squibb (NYSE: BMY) and GRYT Health launched the 'Advocacy Exchange', enhancing the existing COVID Advocacy Exchange to better support patient advocacy organizations. This virtual platform is designed to foster collaboration among advocacy organizations, patients, and industry leaders, providing 24/7 access to educational resources and a searchable resource library. The initiative aims to address health disparities and improve patient experiences through ongoing dialogue and the sharing of best practices.
Bristol Myers Squibb (NYSE:BMY) will release its second quarter 2021 financial results on July 28, 2021, at 8 a.m. ET. Executives will discuss the results during a conference call open to investors and the public. Interested parties can access the live webcast at investor.bms.com or by dialing 888-204-4368 (U.S.) and +1 313-209-4906 (international) using confirmation code 1720109. A replay will be available from 11:30 a.m. ET on July 28 until 11:30 a.m. ET on August 11, 2021.